GlassScriptPhysician profile
Pramodh S Sidhu
NPI 1609804970
$1,471.48
in general payments reported to CMS, 2019-2025
20 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2022: $23.22 · 2023: $616 · 2024: $266 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $320.88 | 2023-2025 | |
| Boston Scientific Corporation | $184.10 | 2023-2025 | Watchman Access System, Bodyguardian |
| Heartflow, INC. | $120.92 | 2020 | |
| Novo Nordisk INC | $115.80 | 2023 | |
| Amgen INC. | $99.20 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $92.03 | 2023-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $73.04 | 2023-2024 | Xarelto |
| Abbott Laboratories | $66.71 | 2024-2025 | Amplatzer Amulet, Mitraclip |
| Philips North America LLC | $53.29 | 2023-2025 | Extended Holter |
| Irhythm Technologies, INC. | $48.37 | 2023 | Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $47.90 | 2024 | |
| Merck Sharp & Dohme LLC | $37.52 | 2023 | Verquvo |
| Edwards Lifesciences Corporation | $32.26 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kiniksa Pharmaceuticals International, Plc | $32.10 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.41 | 2023 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.78 | 2025 | |
| Daiichi Sankyo INC. | $24.27 | 2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $23.80 | 2023 | Eliquis |
| Abbvie INC. | $23.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.88 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pramodh Sidhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.